tetano
Editor, Senior Moderator
J Infect Dis
. 2021 Mar 16;jiab142.
doi: 10.1093/infdis/jiab142. Online ahead of print.
Rapidly Increasing SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced from Plasma Collected During the 2020 Pandemic
Maria R Farcet[SUP] 1 [/SUP], Michael Karbiener[SUP] 1 [/SUP], Julia Schwaiger[SUP] 1 [/SUP], Reinhard Ilk[SUP] 2 [/SUP], Thomas R Kreil[SUP] 1 [/SUP]
Affiliations
Abstract
Immunoglobulin (IG) lots (N=176) released since March 2020 were tested for SARS-CoV-2 neutralizing antibodies, with first positive results for September 2020 lots, mean = 1.7 IU/ml, 46% of lots positive. From there, values steadily increased, in correlation with the cumulative COVID-19 incidence, to reach a mean of 31.2 IU/ml and 93% of lots positive by January 2021. Extrapolating the correlation, IGs could reach an anti-SARS-CoV-2 potency of ~345 IU/ml by July 2021. At that stage, prophylactic IG treatment for primary/secondary immunodeficiency could contain similar doses of anti-SARS-CoV-2 as convalescent plasma which is used for treatment of COVID-19.
Keywords: COVID-19; Primary immunodeficiency; SARS coronavirus 2 antibody potency; SARS-CoV-2; Secondary immunodeficiency; immunoglobulin; intravenous immune globulin; neutralizing antibodies; plasma; prophylaxis.
. 2021 Mar 16;jiab142.
doi: 10.1093/infdis/jiab142. Online ahead of print.
Rapidly Increasing SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced from Plasma Collected During the 2020 Pandemic
Maria R Farcet[SUP] 1 [/SUP], Michael Karbiener[SUP] 1 [/SUP], Julia Schwaiger[SUP] 1 [/SUP], Reinhard Ilk[SUP] 2 [/SUP], Thomas R Kreil[SUP] 1 [/SUP]
Affiliations
- PMID: 33725725
- DOI: 10.1093/infdis/jiab142
Abstract
Immunoglobulin (IG) lots (N=176) released since March 2020 were tested for SARS-CoV-2 neutralizing antibodies, with first positive results for September 2020 lots, mean = 1.7 IU/ml, 46% of lots positive. From there, values steadily increased, in correlation with the cumulative COVID-19 incidence, to reach a mean of 31.2 IU/ml and 93% of lots positive by January 2021. Extrapolating the correlation, IGs could reach an anti-SARS-CoV-2 potency of ~345 IU/ml by July 2021. At that stage, prophylactic IG treatment for primary/secondary immunodeficiency could contain similar doses of anti-SARS-CoV-2 as convalescent plasma which is used for treatment of COVID-19.
Keywords: COVID-19; Primary immunodeficiency; SARS coronavirus 2 antibody potency; SARS-CoV-2; Secondary immunodeficiency; immunoglobulin; intravenous immune globulin; neutralizing antibodies; plasma; prophylaxis.